Answers are grounded in this paper and cite their sources.
Janssen has been at the forefront of the recent pharmaceutical industry trend towards more transparency and sharing of clinical trials data, committing early on to make its data available for both internal and external innovation. Janssen is also committed to protecting patient privacy and giving individuals a voice on how their data is used and disclosed. This paper outlines Janssen’s data-sharing initiatives and describes how it is using leading-edge privacy-enhancing technologies (PETs) to mitigate privacy risks and find the right balance between innovation and privacy.
No takes yet. Share an insight, caveat, or question.
S. P. Bamford (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: